GlobeNewswire

PCI Biotech: Update on operational implications of the corona pandemic

Share

Oslo, Norway, 25 March, 2020: PCI Biotech (OSE: PCIB) has closely monitored potential implications on its short- and long-term operations following the latest development of the coronavirus pandemic. PCI Biotech’s over-riding priority is the safety of its staff, patients participating in the clinical trial and its collaborators.

The main identified near-term implications concern the RELEASE study in bile duct cancer, a rare disease with no approved treatment alternatives. The pandemic has negatively impacted both the opening of new sites and new patient enrolment into the trial, by postponement of site activation dates, and by the changing priorities and physical constraints that are being implemented at the hospitals as a consequence of the pandemic. Since the Q4 2019 reporting an additional 4 sites have been activated, meaning that 34 of the originally planned 40 sites in Europe and US are currently activated. In addition, PCI Biotech has made regulatory progress in the process of adding Asian sites into the RELEASE study, having secured recently regulatory approval in Taiwan. PCI Biotech has not identified any major short-term shortage in supplies of investigational products and devices for the trial. The main priorities are now identification and implementation of potential mitigating actions for RELEASE study progress during the pandemic, as well as the previously communicated opportunities for removal of unnecessary recruitment hurdles in the study protocol. PCI Biotech has per date of this announcement not a complete picture of the long-term consequences regarding timelines and costs for the RELEASE study, but short-term delays and increased costs are expected. For the fimaVacc and the fimaNAc programmes the main identified implications are short-term downturn in business development activities.

PCI Biotech has a solid cash position, placed in NOK and EUR, and neither the going concern assumption nor the previously reported preliminary full year 2019 figures are impacted by the pandemic as of date of this announcement.

The status update above is based on PCI Biotech’s current assessment of the situation and subject to changes as the situation evolves. PCI Biotech will update the market as appropriate if there are relevant changes to operations.

For further information, please contact:
Per Walday, CEO
Email: pw@pcibiotech.no
Mobile: +47 917 93 429

About PCI Biotech         
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo                

Forward-looking statements    
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

PRESS RELEASE: NACON: TOYOTA GAZOO RACING BECOMES ESPORTS WRC PRESENTING SPONSOR2.6.2020 07:45:10 CESTPress release

TOYOTA GAZOO RACING BECOMES ESPORTS WRC PRESENTING SPONSOR OFFERING TOYOTA GR YARIS TO THE WINNER Lesquin, June 2nd, 2020 – NACON and its development studio KT Racing, in collaboration with WRC Promoter, are pleased to announce that TOYOTA GAZOO Racing will become the presenting sponsor of the 2020 and 2021 eSports WRC seasons. The announcement celebrates the Japanese manufacturer’s recent unveiling of the all-new Toyota GR Yaris, a pure performance car born from Toyota’s title-winning experience in the World Rally Championship. Equipped with Toyota’s new GR-FOUR intelligent all-wheel drive system and a thrilling 1.6-litre 3-cylinder turbocharged engine delivering 261 DIN hp and 360 Nm of torque, the all-new Toyota GR Yaris promises to be lightweight, powerful and exhilarating – a fitting prize for the eSports WRC Champion! The partnership between TOYOTA GAZOO Racing and NACON will extend into further promotions spanning WRC 8 as well as WRC 9, the latest instalment of the official WRC

EXEL INDUSTRIES :2019-2020 First-Half Results The initial benefits of our reorganization blacked out by the impact of the health crisis and depreciation of goodwill 1st semester 20191st semester 20202.6.2020 07:00:00 CESTPress release

PRESS RELEASE Paris, June 2, 2020 2019-2020 First-Half Results The initial benefits of our reorganization blacked out by the impact of the health crisis and depreciation of goodwill 1st semester 20191st semester 2020in M€Oct 18 - Mar 19Oct 19 - Mar 20Revenue348.9314.3Current Operating Income5.0-1.1%1.4%-0.3%Non-recurring items-4.2-28.9Financial expenses-1.9-1.8(Losses)/gains on foreign exchange2.9-4.4Profit before tax1.7-36.2Tax expense-0.7-0.4Share of profit of associates0.20.2Net income 1.2-36.4 ·Analysis of 2019-2020 first-half results The decline in current operating income over the first-half of 2019-2020 was due primarily to the drop in revenue from Agricultural and Industrial Spraying due to the global health crisis. The reorganization initiated in 2019 produced visible results for the Sugar Beet Harvesting business. With respect to Agricultural Spraying, we expect an improvement by the end of the financial year. The very uncertain macro-economic context, notably as a result of

Mitsubishi Corporation and NTT complete acquisition of 30% stake in HERE Technologies2.6.2020 07:00:00 CESTPress release

June 2, 2020 Amsterdam and Tokyo – HERE Technologies today announced that Mitsubishi Corporation (MC) and Nippon Telegraph and Telephone Corporation (NTT) of Japan have completed their joint acquisition of a 30% ownership stake in the company, after receiving regulatory approvals. HERE welcomes MC and NTT as strategic investors. The two companies have co-invested in HERE via their recently established, jointly owned holding company COCO Tech Holding B.V. in the Netherlands. As a result, HERE now has nine direct and indirect shareholders: Audi, Bosch, BMW Group, Continental, Intel Capital, MC, Mercedes-Benz, NTT and Pioneer.​ Following the transaction, HERE has added two new members to its Supervisory Board: Mr. Yutaka Kyoya, Executive Vice President, Group CEO, Consumer Industry Group, Mitsubishi Corporation; and Mr. Hiroki Kuriyama, Member of the Board, Executive Vice President, Head of Strategic Business Development, NTT. HERE’s broadened shareholder structure supports the company’s

Prosafe SE: Update on financial situation and process with lenders2.6.2020 07:00:00 CESTPress release

Prosafe refers to the information on its financial status and process with lenders that has been provided over time and lastly in the Q1 2020 report published on 26 May 2020. The company has gained support to an extension to the previously reported forbearance arrangement with a majority of its lenders across its USD 1,300 million and USD 288 million facilities from end May 2020 till end June 2020. As part of this, the company will continue to defer making payments of scheduled instalments and interests under both facilities. Similarly, payment of the final instalment owed and due under the seller credit to Cosco for the Safe Notos remains as initially reported on 13 February subject to ongoing discussions with Cosco and the lenders. The company's discussions with its lenders remain constructive. The forbearance arrangement shows support for the company and creates stability to work with lenders to agree a long term financial solution, while lenders reserve their rights. Pending this,

FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer2.6.2020 07:00:00 CESTPress release

Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma Tecentriq combination improved overall survival and progression-free survival compared to the previous standard of careApplication approved under FDA’s Project Orbis initiative and Real-Time Oncology Review pilot programme Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy. “We’re excited that today’s approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancer immunotherapy option to people with this aggressive form of liver cancer,” said Levi Garraway, M.D., Ph.D., Chief Medi

EVS Broadcast Equipment reports update of share buyback program2.6.2020 06:45:00 CESTPress release

Publication on June 2, 2020, before market opening Regulated information – reporting share buyback EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports update of share buyback program EVS Broadcast Equipment reports that the following transactions, conducted within the framework of the share buyback program announced on May 6, 2020, took place between May 25, 2020 and May 29, 2020. DateNumber of shares acquiredAverage price (EUR)Total (EUR)25/05/20202,500 13.7820 34,45526/05/20202,500 13.9834 34,95927/05/20202,500 14.2910 35,72828/05/20202,500 14.8076 37,01929/05/20202,500 14.4971 36,243Total12,50014.2722 178,403 As of May 29, 2020, and since the start of the buyback program, EVS has bought 27,267 shares at an average price of EUR 14,0123, representing in total EUR 382,072. After aforementioned transactions the total number of own shares amounts now to 618,319 shares as of May 29, 2020 (including 607,332 shares already held by the